|
1
|
Kyle RA, Gertz MA, Witzig TE, Lust JA,
Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson
DR, et al: Review of 1027 patients with newly diagnosed multiple
myeloma. Mayo Clin Proc. 78:21–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar SK, Dispenzieri A, Lacy MQ, Gertz
MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et
al: Continued improvement in survival in multiple myeloma: Changes
in early mortality and outcomes in older patients. Leukemia.
28:1122–1128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimopoulos MA, Chen C, Spencer A,
Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj
M, Zeldis JB, et al: Long-term follow-up on overall survival from
the MM-009 and MM-010 phase III trials of lenalidomide plus
dexamethasone in patients with relapsed or refractory multiple
myeloma. Leukemia. 23:2147–2152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar SK, Lee JH, Lahuerta JJ, Morgan G,
Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau
P, et al: Risk of progression and survival in multiple myeloma
relapsing after therapy with IMiDs and bortezomib: A multicenter
international myeloma working group study. Leukemia. 26:149–157.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nijhof IS, van de Donk NWCJ, Zweegman S
and Lokhorst HM: Current and new therapeutic strategies for
relapsed and refractory multiple myeloma: An update. Drugs.
78:19–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ocio EM, Fernández-Lázaro D, San-Segundo
L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T,
García-Gómez A, Delgado M, et al: In vivo murine model of acquired
resistance in myeloma reveals differential mechanisms for
lenalidomide and pomalidomide in combination with dexamethasone.
Leukemia. 29:705–714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Miguel JS, Weisel K, Moreau P, Lacy M,
Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, et
al: Pomalidomide plus low-dose dexamethasone versus high-dose
dexamethasone alone for patients with relapsed and refractory
multiple myeloma (MM-003): A randomised, open-label, phase 3 trial.
Lancet Oncol. 14:1055–1066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Richardson PG, Siegel DS, Vij R,
Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A,
Bahlis N, et al: Pomalidomide alone or in combination with low-dose
dexamethasone in relapsed and refractory multiple myeloma: A
randomized phase 2 study. Blood. 20:1826–1832. 2014. View Article : Google Scholar
|
|
9
|
Dimopoulos MA, Palumbo A, Corradini P,
Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M,
Vacca A, et al: Safety and efficacy of pomalidomide plus low-dose
dexamethasone in STRATUS (MM-010): A phase 3b study in refractory
multiple myeloma. Blood. 128:497–503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moreau P, Dimopoulos MA, Richardson PG,
Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P,
Song K, et al: Adverse event management in patients with relapsed
and refractory multiple myeloma taking pomalidomide plus low-dose
dexamethasone: A pooled analysis. Eur J Haematol. 99:199–206. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
US Department Of Health And Human
Services: Common terminology criteria for adverse events (CTCAE)
version 4.0. United States, National Cancer Institute. 2009.
|
|
12
|
Sriskandarajah P, Pawlyn C, Mohammed K,
Dearden CE, Davies FE, Morgan GJ, Boyd KD and Kaiser MF: The
efficacy and tolerability of pomalidomide in relapsed/refractory
myeloma patients in a ‘real-world’ study: The Royal Marsden
Hospital experience. Leuk Lymphoma. 58:494–497. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maciocia N, Melville A, Cheesman S,
Sharpley F, Ramasamy K, Streetly M, Jenner M, Benjamin R, Schey S,
Maciocia P, et al: Real-world use of pomalidomide and dexamethasone
in double refractory multiple myeloma suggests benefit in renal
impairment and adverse genetics: A multi-centre UK experience. Br J
Haematol. 176:908–917. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ailawadhi S, Mikhael JR, LaPlant BR,
Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK,
Rajkumar SV, et al: Pomalidomide-dexamethasone in refractory
multiple myeloma: Long-term follow-up of a multi-cohort phase II
clinical trial. Leukemia. 32:719–728. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fouquet G, Pegourie B, Macro M, Petillon
MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G,
et al: Safe and prolonged survival with long-term exposure to
pomalidomide in relapsed/refractory myeloma. Ann Oncol. 27:902–907.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gueneau P, Chretien ML, Cransac-Miet A,
Lafon I, Favennec C, Guy J, Caillot D and Boulin M: Efficacy,
safety, and cost of pomalidomide in relapsed and refractory
multiple myeloma. Eur J Haematol. 100:518–525. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palmas A, Piras G, Uras A, Asproni R,
Murineddu M, Monne M, Stradoni R and Latte G: Pomalidomide in
heavily pretreated refractory multiple myeloma: A case report.
Future Oncol. 13:7–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen CC, Parikh K, Abouzaid S, Purnomo L,
McGuiness CB, Hussein M and Wade RL: Real-world treatment patterns,
time to next treatment, and economic outcomes in relapsed or
refractory multiple myeloma patients treated with pomalidomide or
carfilzomib. J Manag Care Spec Pharm. 23:236–246. 2017.PubMed/NCBI
|
|
19
|
Pelligra CG, Parikh K, Guo S, Chandler C,
Mouro J, Abouzaid S and Ailawadhi S: Cost-effectiveness of
pomalidomide, carfilzomib, and daratumumab for the treatment of
patients with heavily pretreated relapsed-refractory multiple
myeloma in the United States. Clin Ther. 39:1986–2005.e5. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ichinohe T, Kuroda Y, Okamoto S, Matsue K,
Iida S, Sunami K, Komeno T, Suzuki K, Ando K, Taniwaki M, et al: A
multicenter phase 2 study of pomalidomide plus dexamethasone in
patients with relapsed and refractory multiple myeloma: The
Japanese MM-011 trial. Exp Hematol Oncol. 5:112016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dimopoulos M, Weisel K, van de Donk NWCJ,
Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la
Rubia J, Mateos MV, et al: Pomalidomide plus low-dose dexamethasone
in patients with relapsed/refractory multiple myeloma and renal
impairment: Results from a phase II trial. J Clin Oncol.
36:2035–2043. 2018. View Article : Google Scholar : PubMed/NCBI
|
